---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-24-000003"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T01:56:43.060185+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC reports prelim 2023 revenue $946M (+35% YoY); guides 2024 rev $600-850M

## Summary
- Unaudited 2023 total revenue $946M (+35% YoY); net product revenue $661M (+23% YoY).
- DMD franchise: Translarna $355M, Emflaza $255M; Evrysdi royalty/collab revenue $278M.
- 2024 revenue guidance $600-850M (decline); GAAP R&D+SG&A $740-835M; non-GAAP $660-755M.
- Sepiapterin MAA in EU Q1, NDA in US by Q3; PTC518 HD interim data Q2.
- CHMP opinion on Translarna re-examination late Jan 2024; $1B Royalty Pharma deal closed.

## SEC filing metadata
- accession: 0001070081-24-000003
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000003/0001070081-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000003/tmb-20240108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-24-000003
- JSON: https://secwatch.observer/filing/0001070081-24-000003.json
- Plain text: https://secwatch.observer/filing/0001070081-24-000003.txt

## Key facts
- Earnings Releases
  PTC THERAPEUTICS, INC. reported full year 2024 results: revenue $600 million to $850 million. Guidance initiated.
  - Period: full year 2024
  - Revenue: $600 million to $850 million
  - Guidance: initiated
  - Result: guidance update
  source text: PTC anticipates total revenues for the full year 2024 to be between $600 million and $850 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000003/0001070081-24-000003-index.htm
- Earnings Releases
  PTC THERAPEUTICS, INC. reported full year 2023 results: revenue $946 million.
  - Period: full year 2023
  - Revenue: $946 million
  - Result: preliminary results
  source text: Total unaudited net revenue for full year 2023 was approximately $946 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000003/0001070081-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.